OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2019 to Jul 2024
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the execution
of new agreements to expand distribution of OraSure’s
cryosurgical wart removal product by Genomma Lab in the over-the-counter
(“OTC”) or consumer
retail market in Central and South America. In addition, the parties
renewed and extended their prior distribution arrangement for Mexico and
signed a new agreement to distribute the product in South Africa.
Under the agreements, the product will be manufactured by OraSure and
sold under the POINTTS tradename by the Genomma Lab affiliates of
Producciones Infovision, S.A. de C.V. to pharmacies and retailers in
Mexico, Brazil, Argentina, a number of other Central and South American
countries, and South Africa.
“We are pleased to expand our collaboration
with Genomma Lab to make our cryosurgical wart removal product widely
available to the consumer markets in Latin America,”
said Douglas A. Michels, President and CEO of OraSure Technologies. “Our
initial launch in Mexico was extremely successful and set the stage for
a broader relationship. We believe Central and South America represent
an important opportunity to expand our OTC cryosurgical business
significantly in the international marketplace.”
“There is a large market demand for an
over-the-counter cryosurgical wart removal product in Central and South
America, and we are thrilled to be able to incorporate the POINTTS
product into our extensive line of personal care products to help meet
this need,” said Rodrigo Herrera Aspra,
Genomma Lab President. ”We look forward to a
successful collaboration with OraSure Technologies.”
The POINTTS wart removal product consists of a small aerosol canister
containing a refrigerant, and a package of 12 foam buds attached to
hollow tube applicators. In order to treat a common or plantar wart, the
foam bud applicator is inserted into the nozzle of the canister,
refrigerant is dispensed in order to freeze the foam bud and the bud is
then applied to the affected area.
About OraSure Technologies
In addition to cryosurgical products which are sold in both the
professional and consumer markets, OraSure Technologies develops,
manufactures and markets oral fluid specimen collection devices using
proprietary oral fluid technologies, diagnostic products including
immunoassays and other in vitro diagnostic tests. These products are
sold in the United States as well as internationally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, distributors, government agencies,
physicians’ offices, and commercial and
industrial entities.
OraSure Technologies is the leading supplier of oral fluid collection
devices and assays to the life insurance industry and public health
markets for the detection of antibodies to HIV. In addition, the Company
supplies oral fluid testing solutions for drugs of abuse testing. For
more information on the Company, please go to www.orasure.com.
About Producciones Infovision
Producciones Infovision is a leading industrial group in Mexico with
interests in manufacturing, distribution, retail and television
production.
Genomma Lab is a wholly-owned subsidiary of Producciones Infovision that
develops, makes and commercializes pharmaceutical, and cosmetic products.
For more information on Producciones Infovision and Genomma Lab, please
go to www.genommalab.com.
Important Information
This press release contains certain forward-looking statements,
including with respect to product sales, launches and markets. Actual
results could be significantly different. Factors that could affect
results include the ability to market and sell products; changes in
relationships, including disputes or disagreements, with strategic
partners and reliance on strategic partners for the performance of
critical activities under collaborative arrangements; failure of
distributors or other customers to meet purchase forecasts or minimum
purchase requirements for the Company’s
products; impact of competitors, competing products and technology
changes; ability to develop, commercialize and market new products;
market acceptance of oral fluid testing or other products; changes in
market acceptance of products based on product performance; continued
bulk purchases by customers, including governmental agencies, and the
ability to fully deploy those purchases in a timely manner; ability to
fund research and development and other products and operations; ability
to obtain and maintain new or existing product distribution channels;
reliance on sole supply sources for critical product components;
availability of related products produced by third parties or products
required for use of our products; ability to obtain, and timing and cost
of obtaining, necessary regulatory approvals for new products or new
indications or applications for existing products; ability to comply
with applicable regulatory requirements; history of losses and ability
to achieve sustained profitability; volatility of our stock price;
uncertainty relating to patent protection; uncertainty and costs of
litigation relating to patents and other intellectual property;
availability of licenses to patents or other technology; ability to
enter into international manufacturing agreements; obstacles to
international marketing and manufacturing of products; ability to sell
products internationally; loss or impairment of sources of capital;
ability to meet financial covenants in agreements with financial
institutions; ability to retain qualified personnel; exposure to patent
infringement, product liability and other types of litigation; changes
in international, federal or state laws and regulations; customer
consolidations and inventory practices; equipment failures and ability
to obtain needed raw materials and components; the impact of terrorist
attacks and civil unrest; ability to complete consolidation or
restructuring activities; ability to identify, complete and realize the
full benefits of potential acquisitions; and general political, business
and economic conditions. These and other factors are discussed more
fully in the Securities and Exchange Commission (“SEC”)
filings of OraSure Technologies, including its registration statements,
its Annual Report on Form 10-K for the year ended December 31, 2006, its
Quarterly Reports on Form 10-Q, and its other filings with the SEC.
Although forward-looking statements help to provide complete information
about future prospects, readers should keep in mind that forward-looking
statements may not be reliable. OraSure Technologies undertakes no duty
to update any forward-looking statements after they are made.